| Revision as of 01:18, 19 July 2007 editFunPika (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers6,765 editsm Requesting speedy deletion (CSD g5). using TW← Previous edit | Revision as of 03:53, 19 July 2007 edit undoOakshade (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers17,272 edits Very notable drug with a great amount of press coverage. ad hominem arguement against article creatorNext edit → | ||
| Line 1: | Line 1: | ||
| {{db-banned}} | |||
| '''Satraplatin''' is a ] compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. ] (FDA) approval and is not available in retail pharmacies. | '''Satraplatin''' is a ] compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. ] (FDA) approval and is not available in retail pharmacies. | ||
Revision as of 03:53, 19 July 2007
Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
The drug is taken by mouth. It is made available in the United States jointly by Spectrum Pharmaceuticals and GPCbiotech under the name Spera.
The drug has also been used in the treatment of lung and ovarian cancers. The mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing.
References
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |